Mechanistic comparison of mepenzolate bromide and oxotremorine methiodide based on molecular target overlap from BindingDB and ChEMBL binding affinity data.
2
Shared Targets
40%
Jaccard Similarity
40%
IDF-Weighted Similarity
Jaccard measures raw target overlap. IDF-weighted downweights promiscuous hub targets (e.g. CYP enzymes) that bind many compounds non-specifically.
mepenzolate and oxotremorine share 2 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.400 means 40% of the combined target set is bound by both compounds. The IDF-weighted score of 0.397 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do mepenzolate and oxotremorine have in common?
mepenzolate and oxotremorine share 2 molecular targets with a Jaccard similarity of 40%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can mepenzolate and oxotremorine be combined?
mepenzolate and oxotremorine share 2 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: mepenzolate or oxotremorine?
Both mepenzolate and oxotremorine have substantial PubMed research. View their individual profiles for full evidence scores.